What it means
Patent protection can prevent competitors from using a claimed invention without permission during the relevant term, and when that protection ends the business may lose part of the barrier supporting its sales and pricing. A highly concentrated product portfolio can make the effect abrupt.
In pharmaceuticals, generic entry can change the competitive position of an established medicine, as the originator may face lower prices, lost volume, or both. The size and speed of the change are commercial questions, not consequences that one expiry date alone completely predicts.
Regulatory exclusivity is also distinct from a patent, and the US FDA explains that patents and exclusivity arise under different statutes and may or may not run concurrently. Exclusivity concerns certain restrictions or delays on approval of competing medicines when statutory requirements are met.
This distinction matters to forecasting, because expiry of a listed patent does not itself prove a competitor can immediately launch an approved substitute, and an exclusivity period ending does not establish that every relevant patent has expired or is unenforceable. The FDA illustration is specific to the US drug framework.
Other countries have their own patent, regulatory, and market-access conditions, so a global company may face different competitive timing across markets for the same product. Revenue concentration measures how much of the business is exposed.
A company earning most of its sales from one protected product has a different planning problem from a diversified company with several independent products. Concentration is useful, but it does not replace a product-by-product assessment.
Management can prepare scenarios for prices, volumes, and competitor entry dates. The scenarios should also reflect costs that will remain even after revenue falls.
A sales decline and a profit decline are not identical when manufacturing, research, and overhead costs adjust at different speeds. Identify the exposure before a cash shortage, separate legal protection from commercial forecasts, and explain assumptions.
Optimistic forecasts can hide funding needs.
In practice
Real-world examples.
Example
A fictional medicine generates $300 million of a company's $500 million annual revenue. Management expects an important patent to expire and models several competitor-entry dates.
Example
A business labels a forecast date as patent expiry, but its legal team identifies separate regulatory exclusivity. The forecast team checks both protections and the competitor approval assumptions.
Example
An originator forecasts a lower product price but unchanged unit volume after competition begins. The commercial team also tests a scenario with reduced demand.
Formula
Calculation
Product revenue = net selling price per unit x units sold, using consistent measures and periods.
Illustratively, a product sells one million units at $100 each, generating $100 million. A scenario with a $60 price and 800,000 units produces $48 million, a $52 million decline.
Revenue decline percentage = ($100 million - $48 million) / $100 million x 100 = 52%. This is a hypothetical scenario, not an industry rule or profit calculation; costs, rebates, currency, and other factors may require separate modelling.Case study
Seen in the real world.
Fictional case study: Meridian Therapeutics expects competition for its leading product. Its first plan assumes a replacement product launches in time and fully offsets the lost sales. The finance and development teams test a delayed launch, earlier competitive entry, and a slower cost reduction.
They distinguish patent dates from regulatory exclusivity and verify market-specific assumptions with qualified advisers. Meridian retains separate funding plans for the scenarios rather than calling its pipeline a guaranteed replacement. The exercise does not prevent competition, but it exposes the period when cash and operating capacity could be under the most pressure.
Watch out
Common mistakes.
- Assuming one patent date describes every relevant market barrier. Patents, regulatory exclusivity, approvals, and jurisdictions can differ.
- Treating revenue at risk as revenue guaranteed to disappear. Model price, volume, and competitor timing rather than impose an unsupported fixed decline.
- Counting pipeline products as certain replacements. Development, approval, and commercial uptake remain uncertain.
Questions
People also ask.
Does the term apply only to medicines?
No. Other patent-dependent businesses can face a similar exposure, although the phrase is especially common in pharmaceuticals.
Are patents and regulatory exclusivity the same?
No. The FDA explains their separate legal bases and potentially different periods in the US drug context. Check the relevant jurisdiction and product.
What should managers monitor?
Product concentration, verified protection dates, competitor approvals and entry assumptions, price and volume scenarios, replacement-product progress, and the resulting funding need.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%